Baxter Securities Suit Over Novum IQ Pump Faults Draws Investor Calls as Lead‑Plaintiff Deadline Nears

The case stems from Baxter's July 31 halt of Novum IQ pump shipments following disclosures of serious injuries plus two deaths.

Overview

Investor law firms Bernstein Liebhard, Kirby McInerney, and Faruqi & Faruqi are inviting Baxter shareholders to seek lead‑plaintiff status by December 15, 2025.
The putative class period spans purchases of Baxter securities from February 23, 2022 through July 30, 2025.
The complaints assert that Baxter misled investors by concealing systemic Novum IQ Large Volume Pump defects causing underinfusion, overinfusion, and non‑delivery risks.
Baxter issued a customer alert in April and a second notice on July 14 that reported 79 serious‑injury cases plus two patient deaths tied to the pump.
On July 31 Baxter paused shipments and planned installations of the Novum IQ pump, and its shares fell about 22.4% to close at $21.76.